

REVIEW ARTICLE

Understanding Transfusion Therapy in Obstetrics: Ensuring Maternal and Fetal Health

*Obeagu, E.I.¹, Obeagu, G.U.² and Aja, P.M.^{3,4}

¹Department of Medical Laboratory Science, Kampala International University, Uganda.

²School of Nursing Science, Kampala International University, Uganda.

³Department of Biochemistry, Faculty of Science, Ebonyi State University, P.M.B. 053 Abakaliki, Ebonyi State, Nigeria

⁴Department of Biochemistry, Kampala International University, Western Campus, Uganda

ABSTRACT

Transfusion therapy plays a pivotal role in obstetrics, serving as a critical intervention to address various maternal and fetal health challenges. The review encompasses the indications, types, and implications of transfusion therapy, aiming to provide a thorough understanding of its role in ensuring optimal outcomes for both mother and fetus. Obstetric hemorrhage remains a leading cause of maternal morbidity and mortality globally. Transfusion therapy, involving the administration of blood and blood products, emerges as a cornerstone in the management of obstetric hemorrhage, offering a lifeline in critical situations. This abstract delves into the specific scenarios, such as postpartum hemorrhage and placental abruption, where timely transfusions are essential to prevent severe complications. Anemia, a prevalent concern in pregnancy, necessitates a nuanced approach to transfusion therapy. Understanding the thresholds for transfusion in the context of pregnancy-related anemia is crucial for balancing the benefits against potential risks. This review discusses the challenges in managing anemia, exploring the role of transfusion in alleviating symptoms and optimizing maternal and fetal health. In conclusion, this paper synthesizes the current knowledge on transfusion therapy in obstetrics, emphasizing its pivotal role in managing obstetric hemorrhage, anemia, and blood disorders. By elucidating the intricacies of transfusion therapy and its implications for maternal and fetal health, this review aims to guide healthcare professionals in making informed decisions, ultimately contributing to enhanced obstetric care and improved outcomes for pregnant individuals and their infants.

Keywords: Pregnancy outcomes, Obstetrics, Antioxidants, Maternal health, Fetal health, Oxidative stress.

***Corresponding Author**

Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161.

Citing this article

Obeagu, E.I., Obeagu, G.U. and Aja, P.M.. Understanding Transfusion Therapy in Obstetrics: Ensuring Maternal and Fetal Health. KIU J. Health Sci, 2023; 3(2);

Conflict of Interest: None is declared

INTRODUCTION

Transfusion therapy in obstetrics constitutes a critical element in the comprehensive management of maternal hemorrhage, a foremost cause of maternal mortality globally (1). Obstetric hemorrhage, often unforeseen and rapid in onset, poses substantial risks to both maternal and fetal health, necessitating immediate and effective interventions (2). Transfusion therapy, encompassing the administration of blood and blood products, serves as a cornerstone in stabilizing maternal hemodynamics, restoring adequate oxygenation, and addressing coagulopathies during obstetric emergencies (3-7). Transfusion therapy in obstetrics encompasses a multifaceted approach involving the timely and judicious utilization of blood components to address acute maternal bleeding, which frequently arises from complications such as postpartum hemorrhage, placental abruption, uterine atony, or surgical procedures. This therapeutic intervention comprises various blood products, including packed red blood cells (PRBCs), fresh frozen plasma (FFP), platelets, and cryoprecipitate, tailored to address specific hematological deficits and coagulation abnormalities (2).

The primary indication for transfusion in obstetrics revolves around scenarios of severe maternal hemorrhage, either during childbirth or associated with obstetric interventions. Indications include excessive bleeding post-delivery, placental abruption leading to maternal blood loss, coagulopathy, or bleeding complications during obstetric surgeries, where rapid restoration of blood volume and clotting factors is imperative (8). Early identification and prompt intervention are paramount in managing obstetric hemorrhage. Immediate administration of appropriate blood products assists in stabilizing the mother's condition, restoring blood volume, and supporting hemostasis, thereby mitigating the risk of severe maternal complications. While transfusion therapy is life-saving, it necessitates careful consideration of

potential risks such as transfusion reactions, fluid overload, or transmission of infectious agents. The decision to transfuse should be based on clinical necessity, balancing the potential benefits against the associated risks, and individual patient considerations. Efforts to optimize transfusion strategies should also consider potential effects on fetal circulation and oxygenation. Balancing maternal needs with fetal well-being is crucial to minimizing adverse effects on the fetus during the administration of blood products. Ensuring adherence to established transfusion protocols, constant monitoring for adverse events, and continual quality improvement measures are essential components of transfusion therapy in obstetrics.

Despite the life-saving potential, challenges persist in transfusion therapy, including issues related to timely availability of blood products, logistical constraints, and minimizing transfusion-related complications. Future directions involve advancements in research exploring alternative therapies and hemostatic agents to reduce reliance on allogeneic blood products and enhance safety in transfusion practices (1). Transfusion therapy stands as a pivotal intervention in managing obstetric hemorrhage, preserving maternal stability, and optimizing fetal outcomes. Striking a delicate balance between clinical necessity and potential risks is pivotal in ensuring the safe and effective utilization of transfusion therapy in obstetrics. Continued research endeavors and advancements in transfusion strategies promise to refine approaches, ultimately contributing to improved maternal and fetal health outcomes in obstetric care.

Understanding Transfusion Therapy

Transfusion therapy in obstetrics represents a critical component of managing obstetric emergencies, specifically addressing maternal hemorrhage—a leading cause of maternal morbidity and mortality worldwide. This therapy involves the strategic administration of blood and blood products to stabilize maternal hemodynamics, correct anemia, and address coagulopathies during high-risk obstetric scenarios (2). The essence of transfusion

therapy lies in its multifaceted approach, where the prompt delivery of blood components is tailored to counteract severe maternal bleeding, often stemming from postpartum hemorrhage, placental abruption, uterine atony, or complications during childbirth. Blood products utilized in transfusion therapy encompass packed red blood cells (PRBCs), fresh frozen plasma (FFP), platelets, and clotting factors, each addressing specific deficits integral to restoring maternal health (9).

Maternal hemorrhage, notably postpartum hemorrhage, stands as the most common indication for transfusion therapy in obstetrics. Other indications include placental abruption, coagulopathies such as disseminated intravascular coagulation (DIC), or excessive bleeding following obstetric procedures, necessitating swift restoration of blood volume and clotting factors to prevent maternal decompensation. Early recognition of obstetric hemorrhage is paramount, triggering swift and effective interventions. Immediate administration of appropriate blood products assists in correcting hypovolemia, restoring hemostasis, and mitigating maternal complications (3). The decision to initiate transfusion weighs the urgency of maternal stabilization against potential risks, including transfusion reactions, transfusion-associated infections, or fluid overload. An individualized approach, considering the clinical scenario and patient-specific factors, guides transfusion strategies.

While addressing maternal needs, care is taken to minimize potential adverse effects on the fetus. Understanding the impact of transfusion on fetal circulation and oxygenation is crucial in preserving fetal well-being during maternal resuscitation. Adherence to established transfusion protocols, vigilance for adverse events, and continual quality assessment form the backbone of safe transfusion practices in obstetrics. Challenges persist in optimizing transfusion therapy, encompassing logistical hurdles in timely blood product availability,

ensuring compatibility, and minimizing transfusion-associated risks. Future directions entail advancements in research exploring alternative therapies, such as cell salvage techniques and hemostatic agents, to reduce reliance on allogeneic blood products and enhance safety profiles. Transfusion therapy serves as a vital arm in managing obstetric hemorrhage, ensuring maternal stability, and ultimately safeguarding fetal well-being (11). The balance between timely intervention, minimizing risks, and continuous quality improvement measures underpins the efficacy of transfusion therapy in obstetrics. Advancements in this field promise to refine strategies, ultimately contributing to improved maternal and fetal health outcomes in high-risk obstetric scenarios.

Indications for Transfusion

Indications for transfusion in obstetrics encompass various scenarios where the administration of blood or blood products becomes necessary to address maternal hemorrhage, coagulopathies, or anemia (11). Excessive bleeding following childbirth, often considered the most common indication for transfusion in obstetrics. It can result from uterine atony, retained placental tissue, trauma, or complications during cesarean section. A condition where the placenta detaches prematurely from the uterine wall, leading to maternal bleeding. Transfusion may be necessary to manage the resulting blood loss.

Lack of normal uterine muscle tone after childbirth, which can lead to significant postpartum bleeding. Transfusion may be required to support hemostasis and restore blood volume. Obstetric surgeries, such as cesarean sections or procedures to manage postpartum bleeding, may lead to excessive blood loss requiring transfusion of blood products. (12) **Coagulopathies and Disseminated Intravascular Coagulation (DIC)** are conditions characterized by abnormal clotting, leading to either excessive bleeding or thrombotic events (13). Transfusion of clotting factors, platelets, or fresh frozen plasma (FFP) may be necessary to address these abnormalities. Severe anemia due to various causes

during pregnancy or delivery may necessitate transfusion to improve oxygen-carrying capacity and prevent maternal complications. In cases where there is significant blood loss from the fetus to the mother's circulation, transfusion may be required to restore maternal blood volume and maintain hemodynamic stability (14). It's crucial to note that each indication for transfusion in obstetrics requires careful assessment and consideration of the specific clinical circumstances. The decision to initiate transfusion is based on a comprehensive evaluation of the severity of bleeding, hemodynamic status, laboratory parameters, and the individual patient's condition, with the aim of optimizing maternal well-being and preserving fetal health when feasible.

Optimizing Maternal and Fetal Health

Optimizing maternal and fetal health during transfusion therapy in obstetrics is paramount, requiring a delicate balance between addressing maternal needs and considering potential effects on the fetus. Prompt recognition of obstetric hemorrhage and immediate initiation of appropriate transfusion therapy are vital. Timely intervention helps stabilize the mother's condition, restore blood volume, and maintain tissue perfusion, thereby preventing severe maternal complications (15). The decision to initiate transfusion should consider the clinical necessity based on the severity of bleeding, hemodynamic instability, laboratory parameters, and the overall clinical status of the patient. An individualized approach tailored to the specific needs and risks of the mother is pivotal (16). Healthcare providers must carefully assess the benefits of transfusion against potential risks, including transfusion reactions, fluid overload, or transmission of infections. This assessment is crucial to minimize risks to both the mother and the fetus (17).

Continual monitoring of maternal vital signs, laboratory parameters, and fetal well-being during transfusion therapy is essential. Adhering to established transfusion protocols and

guidelines ensures safe and effective administration of blood products (18). While addressing maternal needs, efforts are made to minimize potential adverse effects on the fetus. Understanding the impact of transfusion on fetal circulation, oxygenation, and hemodynamics guides healthcare providers in making decisions that aim to safeguard fetal well-being. Open communication between healthcare providers and patients regarding the necessity, risks, and benefits of transfusion therapy is crucial. Informed consent ensures that patients understand the implications of transfusion and actively participate in decision-making (19). Post-transfusion, ongoing monitoring of maternal and fetal status is necessary to assess the effectiveness of the intervention and identify any potential adverse reactions or complications (20). A multidisciplinary approach involving obstetricians, hematologists, anesthesiologists, and neonatologists ensures comprehensive care, considering both maternal and fetal aspects throughout transfusion therapy (21). Optimizing maternal and fetal health during transfusion therapy in obstetrics involves a nuanced approach that prioritizes maternal stabilization while minimizing potential risks to the fetus (22). Individualized care, close monitoring, adherence to protocols, and shared decision-making contribute to safer and more effective transfusion practices, ultimately ensuring the best possible outcomes for both mother and child.

Challenges and Future Directions

Early recognition of obstetric complications requiring transfusion therapy remains a challenge, particularly in resource-limited settings. Delayed identification and initiation of treatment can significantly impact outcomes. Implementing educational programs for healthcare providers and improving access to essential resources can enhance the timely recognition and initiation of transfusion therapy. Anemia in pregnancy is a multifactorial condition, and determining the optimal threshold for transfusion remains challenging. Balancing the benefits of transfusion against potential risks is complex. Research on individualized approaches, considering factors such as gestational age, underlying causes of anemia, and maternal health

status, can guide more targeted transfusion strategies. Ensuring a stable and safe supply of blood products is a global challenge. Many regions face shortages, and safety concerns, such as infections and alloimmunization, persist. Developing strategies to improve blood product availability, implementing rigorous screening and testing protocols, and exploring alternative therapies, such as artificial blood substitutes, are critical areas for future research (23-24).

Pregnant individuals with pre-existing blood disorders pose unique challenges in terms of transfusion therapy. The delicate balance between managing maternal health and preventing harm to the fetus is a complex clinical scenario. Conducting prospective studies on the safety and efficacy of transfusion therapy in specific blood disorders during pregnancy, and developing consensus guidelines, can provide much-needed guidance for clinicians. While advancements in transfusion medicine, such as pathogen reduction technologies, have improved safety, their accessibility in various healthcare settings remains a challenge. Expanding the adoption of novel technologies, improving cost-effectiveness, and conducting real-world studies on their implementation can pave the way for safer and more efficient transfusion practices. Limited prospective data on the long-term maternal and fetal outcomes following transfusion therapy pose challenges in understanding the true impact of interventions. Longitudinal studies assessing not only immediate outcomes but also the potential implications on neurodevelopment, cardiovascular health, and overall quality of life for both mother and child can provide valuable insights. Disparities in transfusion practices and access to education exist globally. Bridging these gaps is essential for ensuring consistent and high-quality care for pregnant individuals worldwide. Fostering global collaboration, sharing best practices, and investing in educational initiatives can contribute to standardizing transfusion therapy protocols and improving outcomes on a global scale (25-26).

Conclusion

This paper has highlighted key challenges and outlined potential future directions to further optimize outcomes for pregnant individuals and their infants. The challenges in timely recognition of obstetric complications requiring transfusion, determining optimal thresholds for anemia management, ensuring the availability and safety of blood products, and managing blood disorders during pregnancy underscore the need for ongoing research and innovation. Individualized approaches, advancements in transfusion medicine, and a global collaborative effort are essential to address these challenges comprehensively.

REFERENCE

1. Biji KP, RAShmi R, ReKhA K, VINEETHA P, ABIDA B. Protocol Based Blood Management in Major Obstetric Haemorrhage-A Case Series. *Journal of Clinical & Diagnostic Research*. 2021;15(8).
2. World Health Organization. Clinical management of obstetric and neonatal emergencies in Africa. 2022.
3. Chalkias A, Jarzebowski M, Rosenblatt K, editors. *Current Topics in Critical Care for the Anesthesiologist, An Issue of Anesthesiology Clinics*, E-Book. Elsevier Health Sciences; 2023.
4. Obeagu EI, Ubosi NI, Uzoma G. Maternal Hemorrhage and Blood Transfusions: Safeguarding Pregnancy Health. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2023;10(11):26-35.
5. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Ugwu OP. Immunomodulatory Effects of Transfusions on Maternal Immunity in Pregnancy. *APPLIED SCIENCES (NIJBAS)*. 2023;3(3).
6. Obeagu EI, Obeagu GU, Adepoju OJ. Evaluation of haematological parameters of pregnant women based on age groups in Olorunsogo road area of Ido, Ondo state. *J. Bio. Innov11* (3). 2022:936-41.
7. Obeagu EI, Babar Q, Obeagu GU. Allergic blood

- Transfusion reaction: A Review. *Int. J. Curr. Res. Med. Sci.* 2021;7(5):25-33.
8. Owen MD, Cassidy AL, Weeks AD. Why are women still dying from obstetric hemorrhage? A narrative review of perspectives from high and low resource settings. *International journal of obstetric anaesthesia.* 2021; 46:102982.
 9. Minckas N. Experience matters: women's experience of care during facility-based childbirth. A mixed-methods study on postpartum outcomes (Doctoral dissertation, UCL (University College London)). 2023.
 10. World Health Organization. Clinical management of obstetric and neonatal emergencies in Africa. 2022.
 11. Allard S, Contreras M. Clinical blood transfusion. *Postgraduate Haematology.* 2015:214-45.
 12. Jansen AJ, van Rhenen DJ, Steegers EA, Duvekot JJ. Postpartum hemorrhage and transfusion of blood and blood components. *Obstetrical & gynecological survey.* 2005;60(10):663-71.
 13. Papageorgiou C, Jourdi G, Adjambri E, Walborn A, Patel P, Fareed J, Elalamy I, Hoppensteadt D, Gerotziafas GT. Disseminated intravascular coagulation: an update on pathogenesis, diagnosis, and therapeutic strategies. *Clinical and applied thrombosis/hemostasis.* 2018;24(9_suppl):8S-28S.
 14. Gupta S, Sharma K, Sharma C, Chhabra A, Jeengar L, Sharma N. Pathophysiologic and anaesthetic considerations in iron deficiency anaemia and pregnancy; An update. *Journal of Obstetric Anaesthesia and Critical Care.* 2021;11(2):59-69.
 15. Kandasamy D, Kumar Selvarajan A, Jeyakumar JD. Outcome of audit and education on blood transfusion practice in obstetrics setting. *Hematology, Transfusion and Cell Therapy.* 2022; 44:151-5.
 16. Guerado E, Medina A, Mata MI, Galvan JM, Bertrand ML. Protocols for massive blood transfusion: when and why, and potential complications. *European Journal of Trauma and Emergency Surgery.* 2016; 42:283-95.
 17. Alam A, Lin Y, Lima A, Hansen M, Callum JL. The prevention of transfusion-associated circulatory overload. *Transfusion medicine reviews.* 2013;27(2):105-12.
 18. David AL, Spencer RN. Clinical Assessment of Fetal Well-Being and Fetal Safety Indicators. *The Journal of Clinical Pharmacology.* 2022 Sep;62: S67-78.
 19. Szczepiorkowski ZM, Dunbar NM. Transfusion guidelines: when to transfuse. *Hematology 2013, the American Society of Hematology Education Program Book.* 2013;(1):638-44.
 20. Girelli G, Antoncechi S, Casadei AM, Del Vecchio A, Isernia P, Motta M, Regoli D, Romagnoli C, Tripodi G, Velati C. Recommendations for transfusion therapy in neonatology. *Blood Transfusion.* 2015;13(3):484.
 21. New HV, Berryman J, Bolton-Maggs PH, Cantwell C, Chalmers EA, Davies T, Gottstein R, Kelleher A, Kumar S, Morley SL, Stanworth SJ. Guidelines on transfusion for fetuses, neonates and older children. *British journal of haematology.* 2016;175(5):784-828.
 22. Hodgins S, Tielsch J, Rankin K, Robinson A, Kearns A, Caglia J. A new look at care in pregnancy: simple, effective interventions for neglected populations. *PloS one.* 2016;11(8): e0160562.
 23. Dayyabu AL. Hemoglobinopathies in Perinatal Medicine: Challenges in Management. Chervenak FA, Kupesic Plavsic S, Kurjak A. *The fetus as a patient: current perspectives.* Jaypee Brothers, New Delhi. 2019:1-8.
 24. Barro L, Drew VJ, Poda GG, Tagny CT, El-Ekiaby M, Owusu-Ofori S, Burnouf T. Blood transfusion in sub-Saharan Africa: understanding the missing gap and responding to present and future challenges. *Vox Sanguinis.* 2018;113(8):726-36.
 25. Sohrabi M, Zandieh M, Afshar-Nadjafi B. An equity-oriented multi-objective inventory management model for blood banks considering the patient condition: A real-life case. *Scientia Iranica.* 2021.
 26. Garraud O, Sut C, Haddad A, Tariket S, Aloui C, Laradi S, Hamzeh-Cognasse H, Bourlet T, Zeni F, Aubron C, Ozier Y. Transfusion-associated hazards: a revisit of their presentation. *Transfusion Clinique et Biologique.* 2018;25(2):118-35.